Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan for In-hospital Hyponatremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non artifactual hyponatremia in euvolemic or hypervolemic states, defined as serum sodium \<135 mEq/L confirmed in at least 2 consecutive evaluations;~* 18 years of age or older;~* Able to give written Informed Consent.~Exclusion Criteria:~* Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods;~* Hyponatremia in hypovolemic states;~* Acute and transient hyponatremia associated with head trauma or post-operative state;~* Hyponatremia due to uncontrolled hypothyroidism or uncontrolled adrenal insufficiency;~* Cardiac surgery within 30 days prior to the potential study enrollment, excluding percutaneous coronary interventions;~* History of a myocardial infarction within 30 days prior to the potential study enrollment;~* History of sustained ventricular tachycardia or ventricular fibrillation within the last 30 days, unless in the presence of an automatic implantable cardioverter defibrillator;~* Severe angina including angina at rest or at slight exertion and/or unstable angina;~* History of a cerebrovascular accident within the last 30 days;~* Subjects with psychogenic polydipsia may not be included, however subjects with other psychiatric illness may be included;~* Systolic arterial blood pressure \<90 mmHg;~* History of hypersensitivity and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril);~* History of drug or medication abuse within the past year, or current alcohol abuse;~* Uncontrolled diabetes mellitus defined as fasting glucose \>300mg/dL;~* Urinary tract obstruction except BPH if non-obstructive;~* Terminally ill or moribund condition with little chance of short-term survival;~* Serum creatinine \>3.5 mg/dL;~* Serum sodium \<120 mEq/L with associated neurologic impairment, i.e. symptoms such as apathy, confusion, seizures;~* Patients with progressive or episodic neurologic disease such as multiple sclerosis or history of multiple strokes;~* Child-Pugh score greater than 10 (unless approved);~* Patients receiving intravenous fluids at a rate greater than KVO (Keep Vein Open);~* Hyponatremia due to lab artifacts;~* Patients receiving AVP or its analogs for treatment of any condition;~* Patients receiving within 7 days of randomization, other medications for treatment of hyponatremia specifically: demeclocycline, lithium carbonate or urea;~* Patients likely requiring IV saline for correction of symptomatic or asymptomatic severe hyponatremia during the course of the study;~* Severe pulmonary artery hypertension;~* Hyponatremia should not be the result of any medication that can safely be withdrawn.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: EXPERIMENTAL): None
- standard therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).